Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

2KEYNOTE-062 (P vs C ; CPS>10), 2020 KEYNOTE-062 (P vs C ; CPS>1), 20202KEYNOTE-062 (PC vs C ; CPS>1), 2020 KEYNOTE-062 (PC vs C ; CPS>10), 2020pembrolizumab alone vs. pembrolizumab plus SoC 1.00 [0.79; 1.27]1.00 [0.79;1.27]pembrolizumab alone vs. pembrolizumab plus SoC 1.00 [0.79; 1.27]pembrolizumab alone vs. Standard of Care (SoC) 0.85 [0.71; 1.01]0.85 [0.71;1.01]pembrolizumab alone vs. Standard of Care (SoC) 0.85 [0.71; 1.01]pembrolizumab plus SoC vs. pembrolizumab alone 1.00 [0.79; 1.27]1.00 [0.79;1.27]pembrolizumab plus SoC vs. pembrolizumab alone 1.00 [0.79; 1.27]pembrolizumab plus SoC vs. Standard of Care (SoC) 0.85 [0.72; 1.00]0.85 [0.72;1.00]pembrolizumab plus SoC vs. Standard of Care (SoC) 0.85 [0.72; 1.00]Standard of Care (SoC) vs. pembrolizumab alone 1.18 [0.99; 1.40]1.18 [0.99;1.40]Standard of Care (SoC) vs. pembrolizumab alone 1.18 [0.99; 1.40]Standard of Care (SoC) vs. pembrolizumab plus SoC 1.18 [1.00; 1.39]1.18 [1.00;1.39]Standard of Care (SoC) vs. pembrolizumab plus SoC 1.18 [1.00; 1.39]Standard of Care (SoC)placebo plus SoCpembrolizumab alonepembrolizumab plus SoCdirect evidencenetwork meta-analysis
T vs. C Standard of Care (SoC)placebo plus SoCpembrolizumab alonepembrolizumab plus SoC
Standard of Care (SoC)---NA1.18
0.99; 1.40		1.18
1.00; 1.39
placebo plus SoCNA---NANA
pembrolizumab alone0.85
0.71; 1.01		NA---1.00
0.79; 1.27
pembrolizumab plus SoC0.85
0.72; 1.00		NA1.00
0.79; 1.27		---

pathologies: 184 - treatments: 873 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons